Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Surgery
Biotech
Genentech shreds RIPK1 inhibitor after ph. 2 failure
An interim analysis revealed flizasertib was unlikely to prevent heart surgery-induced kidney complications in a phase 2 trial.
Darren Incorvaia
Mar 19, 2026 2:48pm
Langer-backed biotech looks to end cancer recurrence
Feb 12, 2026 8:00am
J&J launches AI surgery funding competition with Nvidia, AWS
Jun 25, 2025 10:30am
Top health agency awards $54M for tumor treatment, research
Aug 27, 2024 4:00am
Zimmer Biomet scoops up OrthoGrid to expand hip portfolio
Aug 9, 2024 11:30am
Medline sews up Ecolab's surgical drape business for $950M
May 2, 2024 12:26pm
